CliffBio
small molecule

CLOBETASOL PROPIONATE

CLOBETASOL PROPIONATE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameCLOBETASOL PROPIONATE
Active ingredientCLOBETASOL PROPIONATE
Strength0.05%
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalMarch 2024
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CLOBETASOL PROPIONATE patent cliff — loss of exclusivity — | CliffBio